ARTICLE | Management Tracks
Domain, Initial among quartet of biotechs unveiling CEOs
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
April 19, 2024 12:30 AM UTC
At least four biotechs unveiled new CEOs on Wednesday and Thursday, including a pair of well-funded, early-stage companies, Domain Therapeutics S.A. and Initial Therapeutics Inc.
Sean MacDonald will lead Domain, which is targeting GPCR receptors. He became an adviser to the French company in February 2023 and took on the CBO role in January. ...